Clinical Education InitiativeMenu
Search
Home > Courses > ACTHIV 2017 - The Opioid Epidemic and HIV: The Indiana HIV/HCV Outbreak: Implications for Prevention

ACTHIV 2017 - The Opioid Epidemic and HIV: The Indiana HIV/HCV Outbreak: Implications for Prevention

ACTHIV 2017 - The Opioid Epidemic and HIV: The Indiana HIV/HCV Outbreak: Implications for Prevention
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Presentation: 4/20/2017
Web Posting: 9/15/2017
CE Expiration: 09/15/2018

The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 11th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 20-22, 2017 in Dallas, TX. The Conference was supported by funding from the Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course post-test quiz and follow the instructions.

FACULTY:
John T. Brooks, MD, Senior Medical Advisor to the Division of HIV/AIDS Prevention at the Center for Disease Control and Prevention.

Estimated time to complete: 30 minutes

TARGET AUDIENCE
Physicians (both specialists and primary care/family medicine), nurse practitioners, and nurses who are frontline providers of care to persons at risk of or with HIV infection. Physician assistants, pharmacists, case managers and other healthcare professionals may also participate.

Learning Objectives
As a result of participating in this activity, participants should be better able to:

  • Describe the key demographic changes in persons at risk for hepatitis C virus (HCV) and HIV infection in the United States
  • Identify 3 risk factors associated with increased risk for vulnerability to new HCV or HIV infection among persons who inject drugs
  • Identify 3 effective interventions to reduce the risk of HCV and HIV infections among persons who inject drugs

ACCREDITATION

Physicians:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV). William Beaumont Hospital is accredited by the ACCME to provide continuing medical education for physicians.

William Beaumont Hospital designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners:

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.0 pharmacotherapeutic contact hours).

Physician Assistants:

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category I credit for completing this program.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT

In order to obtain your certificate of credit, you must:

  • read the CME/CE information and review the full content of the activity
  • achieve a passing grade on the post-test (70% or greater), and
  • complete the evaluation.

Your certificate for the activity will be made available immediately to print online.

DISCLOSURES

According to the disclosure policy of Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, ACTHIV or the American Nurses Credentialing Council's Commission on Accreditation. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity contains off-label discussion.

Faculty Disclosure

John T. Brooks, MD, has no relevant financial relationships with commercial interests.

Planner Disclosures

The following planners have indicated they have no relevant financial relationships to disclose: Bruce Agins, MD; John T. Brooks, MD; Gina Brown, MD; Maggie Chartier, PhD, MPH; Vanessa Elharrar, MD, MPH; Monica Gandhi, MD, MPH; John JD Juchniewicz, MCIS, CHCP; Bill G. Kapogiannis, MD; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Edward Moylan, RP; Tonia Poteat, PhD, MPH, PA-C; Asa E. Radix, MD, MPH; Dianne Rausch, PhD; Polly E. Ross, MD; Cheryl Smith, MD; Brooke J. Taylor, MPH, CHCP; Carole Treston, RN, MPH, ACRN, FAAN; Ronald Dean Wilcox, MD; Barbara A. Young, MSW, LCSE, LCADC, SAC

The following planners have indicated they have relevant financial relationships to disclose:

Laura Armas-Kolostroubis, MD: Advisory Board: Bristol-Myers Squibb, Janssen Therapeutics, Theratech; Promotional Speakers Bureau: Gilead Sciences
Roger Bedimo, MD: Advisory Board: Bristol-Myers Squibb, Merck & Co., Theratechnologies; Grant Recipient/Research Support: Merck & Co, Bristol-Myers Squibb.
Carlos del Rio, MD: Board Member: HIVMA, IAS-USA
Donna Futterman, MD: Grant/Research Support: Gilead Sciences
Joel Gallant, MD, MPH: Advisory Boards: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare/ GlaxoSmithKline; Grant/ Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., Sangamo BioSciences, ViiV Healthcare/GlaxoSmithKline
Rajesh Gandhi, MD: Educational - Grant/Research Support: EBSCO, Gilead Sciences, Merck & Co., ViiV Healthcare
Sharon Hillier, PhD: Advisory Board: Merck & Co., Perrigo; Consultant Cepheid, Symbiomix; Grant/Health Support: Symbiomix
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board: Merck & Co.; Consultant: Gilead Sciences, Merck & Co., ViiV Healthcare; Grant/Research Support: Gilead Sciences, ViiV Healthcare; Promotional Speaker's Bureaus: Gilead Sciences, Merck & Co., ViiV Healthcare
Vincent Lo Re, MD, MSCE: Board Member: International Society for Pharmacoepidemiology; Grant/Research Support: AstraZeneca
Michael J. Mugavero, MD, MHSc: Advisory Board: Bristol-Myers Squibb, Gilead Sciences; Consultant: Abt Assoc., Bristol-Myers Squibb, Gilead Sciences, Merck & Co.; Grant/Research Support: Bristol-Myers Squibb
Renslow Sherer, MD: Advisory Board: Gilead Sciences; Grant Recipient/Research Support: Gilead Sciences, Janssen Therapeutics
William R. Short, MD, MPH: Advisory Board: Gilead Sciences, Janssen Therapeutics; Consultant: Gilead Sciences, Janssen Therapeutics; Promotional Speakers Bureaus: Gilead Sciences, Janssen Therapeutics
Kathleen E. Squires, MD: Advisory Board: Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Janssen Therapeutics, ViiV Healthcare; Consultant: Merck & Co.; Grant Recipient/Research Support: Gilead Sciences
Melanie Thompson, MD: Grant Recipient/Research Support: Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Merck & Co., Sharp Dohme, Roche Molecular Systems, TaiMed Biologics, ViiV Healthcare
Andrea Weddle, MSW: Advisory Board (ACA): Janssen Therapeutics
Susan Ellen Weiss, FNP: Advisory Board: Gilead Sciences; Consultant: Gilead Sciences, Merck & Co.; Board Member: AAHIVM; Promotional Speaker's Bureau: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics

Privacy Policy
For more information about Beaumont's privacy policy, please access https://www.beaumont.org/patients-families/patients-rights-privacy/privacy
For more information about Academy privacy policy, please access http://www.academycme.org/privacy.htm

For CME information or credit details, contact: cme@beaumont.edu

For CNE information or credit details, contact: CEServices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2017. American Academy of CME, Inc., William Beaumont Hospital, and American Conference for the Treatment of HIV.

Bibliographic Sources:

Presenter
  • John T. Brooks, MD
    Senior Medical Advisor
    Center for Disease Control and Prevention
Presenter Bio
John Brooks, MD
John T. Brooks, MD currently serves as the Senior Medical Advisor to the Division of HIV/AIDS Prevention at the Center for Disease Control and Prevention. Although his primary area of expertise is HIV infection, Dr. Brooks, has led teams during emergency responses to anthrax (2001), SARS (2003), Hurricane Katrina (2005), and Ebola (2014 and 2015). He served as Incident Manager for the 2015 HCV/HIV Outbreak. Dr. Brooks came to CDC as an EIS officer after completing a residency in internal medicine and a fellowship in infectious disease. Dr. Brooks graduated from Harvard Medical School in 1994, and completed post-graduate clinical training at Brigham and Women’s Hospital and Massachusetts General Hospital in Boston, MA 1994-1997. He continues to see patients at the Atlanta Veterans Administration Hospital’s HIV clinic.